Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $32 to $52.
Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $32 to $52.